<p>在地缘政治紧张局势加剧、通胀担忧持续以及油价波动的背景下，全球市场经历了显著波动，美国股指本周收盘下跌。随着主要经济体的中央银行在这些不确定性中发出谨慎信号并维持利率，投资者越来越关注能够有效应对这些挑战环境的高增长机会，尤其是在科技等领域。</p>
<h3>全球十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 205 只股票的完整列表。</p>
<p>我们将从筛选结果中选取一些进行分析。</p>
<h2>ALTEOGEN (KOSDAQ:A196170)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> ALTEOGEN Inc.是一家生物技术公司，专注于开发长效生物更好药物、专有抗体药物偶联物和抗体生物仿制药，市值为 191.8 亿韩元。</p>
<p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，金额为 2021.8 亿韩元。它专注于开发创新的生物制药产品，如长效生物更好药物和抗体药物偶联物。</p>
<p>Alteogen 展现了令人印象深刻的财务和战略增长，年化收入增长达到 65.5%，盈利增长预测为 80.2%。该公司对创新的承诺通过其研发支出得以体现，这对维持其在竞争激烈的生物技术领域的快速扩张至关重要。最近，Alteogen 与 Biogen 签署了一项有利可图的协议，开发使用其专有 Hybrozyme 技术的皮下制剂，预计将带来超过 5.49 亿美元的里程碑付款以及销售提成。这一合作不仅提升了 Alteogen 的财务前景，还巩固了其在生物制药领域的地位，承诺持续增长和行业相关性。</p>
<ul>
<li>点击这里深入了解 ALTEOGEN 的完整分析健康报告。</li>
<li>在我们的历史部分查看 ALTEOGEN 的历史数据，以跟踪其表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth"/></p>
<p>KOSDAQ:A196170 截至 2026 年 3 月的盈利和收入增长</p>
<h2>Celestica (TSX:CLS)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Celestica Inc.及其子公司在亚洲、北美及全球提供供应链解决方案，市值为 476.7 亿加元。</p>
<p><strong>运营：</strong> Celestica 通过其先进技术解决方案（ATS）和连接与云解决方案（CCS）部门产生收入，其中 CCS 贡献的份额更大，达到 91.9 亿美元，而 ATS 为 32 亿美元。</p>
<p>Celestica 最近展现了强劲的财务表现，过去一年盈利增长显著，达到 94.5%，远超电子行业 17.7% 的增长。这一增长得益于其向高需求领域（如人工智能）的战略转型，通过与 AMD 的合作开发先进的网络交换机以支持 AI 平台。此外，Celestica 在研发方面的承诺通过其在该领域的重大投资得以体现，符合行业向增强技术能力和创新的趋势。该公司还积极管理资本配置，反映在 2025 年 10 月至 2026 年 2 月回购价值 5570 万美元的股票上，显示出对其财务健康和未来前景的信心。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Celestica 的动态。</li>
<li>查看 Celestica 的过去表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown"/></p>
<p>TSX:CLS 截至 2026 年 3 月的收入和支出细分</p>
<h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Zhen Ding Technology Holding Limited 及其子公司涉及印刷电路板产品的设计、开发、制造和销售，市场覆盖美国、中国大陆、台湾和新加坡，市值为 2220.5 亿新台币。</p>
<p><strong>运营：</strong> 该公司专注于印刷电路板（PCB）的设计、开发、制造和销售，从该部门产生 1825.2 亿新台币的收入。</p>
<p>尽管 Zhen Ding Technology Holding 最近净收入从 91.8 亿新台币下降至 67.9 亿新台币，但预计年盈利增长为 41.2%，超过台湾市场平均水平 21.4%。这一强劲的预测得益于其积极的研发投资策略，符合行业向先进技术解决方案的转变。该公司在三月份参与多场高端会议，凸显其在区域技术讨论中的积极角色，增强了其行业影响力，并可能提升未来表现。</p>
<ul>
<li>点击探索我们在振鼎科技控股健康报告中的详细发现。</li>
<li>了解振鼎科技控股的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:4958 截至 2026 年 3 月的收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>点击这里更详细地查看我们全球高增长科技和人工智能股票的 205 家公司名单。</li>
<li>这些公司中有哪一些是你资产组合的一部分吗？利用 Simply Wall St 的投资组合分析功能，全面了解它们的表现。</li>
<li>通过 Simply Wall St 解锁知情投资的力量，这是你在全球股市中导航的免费指南。</li>
</ul>
<h2>寻找新视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容为一般性信息。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> AI 股票筛选器和警报</h3>
<p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
<p>• 分红强劲的公司（收益率 3% 以上）</p>
<p>• 内部人士买入的被低估小型股</p>
<p>• 高增长科技和人工智能公司</p>
<p>或者从 50 多个指标中构建你自己的筛选器。</p>
<p>立即免费探索</p>

科创医药ETF工银

平安中证医疗创新ETF

方正富邦中证医药及医疗器械创新ETF

<p>在地缘政治紧张和通货膨胀的背景下，全球市场波动，美国股指下跌。投资者正关注高增长的科技股。值得注意的公司包括 Hacksaw、巨人网络集团和 CARsgen Therapeutics，它们都显示出令人印象深刻的收入和盈利增长。ALTEOGEN 和 Celestica 因其强劲的财务表现和战略合作伙伴关系而受到关注，而震鼎科技则因尽管近期收入有所下降，但仍展现出良好的盈利增长潜力。报告强调了在应对当前市场挑战中，创新和研发的重要性</p>

<p>Amidst a backdrop of heightened geopolitical tensions, persistent inflation concerns, and volatile oil prices, global markets have experienced significant fluctuations with U.S. equity indexes finishing lower for the week. As central banks across major economies signal caution and maintain interest rates amid these uncertainties, investors are increasingly focused on identifying high growth opportunities in sectors like technology that can navigate such challenging environments effectively.</p>
<div class="lb-trans"><p>在地缘政治紧张局势加剧、通胀担忧持续以及油价波动的背景下，全球市场经历了显著波动，美国股指本周收盘下跌。随着主要经济体的中央银行在这些不确定性中发出谨慎信号并维持利率，投资者越来越关注能够有效应对这些挑战环境的高增长机会，尤其是在科技等领域。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 205 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 205 只股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我们将从筛选结果中选取一些进行分析。</p>
</div><h2>ALTEOGEN (KOSDAQ:A196170)</h2>
<div class="lb-trans"><h2>ALTEOGEN (KOSDAQ:A196170)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ALTEOGEN Inc.是一家生物技术公司，专注于开发长效生物更好药物、专有抗体药物偶联物和抗体生物仿制药，市值为 191.8 亿韩元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its biotechnology segment, amounting to ₩202.18 billion. It focuses on developing innovative biopharmaceutical products such as long-acting biobetters and antibody-drug conjugates.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，金额为 2021.8 亿韩元。它专注于开发创新的生物制药产品，如长效生物更好药物和抗体药物偶联物。</p>
</div><p>Alteogen has demonstrated impressive financial and strategic growth, evidenced by its annualized revenue increase of 65.5% and earnings growth forecast at 80.2%. The company's commitment to innovation is highlighted by its R&amp;D expenses, crucial for sustaining its rapid expansion in the competitive biotech sector. Recently, Alteogen inked a lucrative deal with Biogen for the development of subcutaneous formulations using its proprietary Hybrozyme technology, potentially bringing in over $549 million in milestone payments plus royalties on sales. This partnership not only boosts Alteogen’s financial outlook but also solidifies its standing in biologics, promising sustained growth and industry relevance.</p>
<div class="lb-trans"><p>Alteogen 展现了令人印象深刻的财务和战略增长，年化收入增长达到 65.5%，盈利增长预测为 80.2%。该公司对创新的承诺通过其研发支出得以体现，这对维持其在竞争激烈的生物技术领域的快速扩张至关重要。最近，Alteogen 与 Biogen 签署了一项有利可图的协议，开发使用其专有 Hybrozyme 技术的皮下制剂，预计将带来超过 5.49 亿美元的里程碑付款以及销售提成。这一合作不仅提升了 Alteogen 的财务前景，还巩固了其在生物制药领域的地位，承诺持续增长和行业相关性。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of ALTEOGEN.</li>
<li>Explore historical data to track ALTEOGEN's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 ALTEOGEN 的完整分析健康报告。</li>
<li>在我们的历史部分查看 ALTEOGEN 的历史数据，以跟踪其表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth"/></p>
<p>KOSDAQ:A196170 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>KOSDAQ:A196170 截至 2026 年 3 月的盈利和收入增长</p>
</div><h2>Celestica (TSX:CLS)</h2>
<div class="lb-trans"><h2>Celestica (TSX:CLS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Celestica Inc., along with its subsidiaries, offers supply chain solutions across Asia, North America, and globally, with a market capitalization of CA$47.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Celestica Inc.及其子公司在亚洲、北美及全球提供供应链解决方案，市值为 476.7 亿加元。</p>
</div><p><strong>Operations:</strong> Celestica generates revenue through its Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS) segments, with CCS contributing a larger share at $9.19 billion compared to ATS's $3.20 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Celestica 通过其先进技术解决方案（ATS）和连接与云解决方案（CCS）部门产生收入，其中 CCS 贡献的份额更大，达到 91.9 亿美元，而 ATS 为 32 亿美元。</p>
</div><p>Celestica has recently demonstrated robust financial performance, with a notable 94.5% surge in earnings over the past year, significantly outpacing the electronics industry's growth of 17.7%. This growth is underpinned by a strategic pivot towards high-demand sectors like AI through partnerships, such as their recent collaboration with AMD to develop advanced networking switches for AI platforms. Furthermore, Celestica's commitment to R&amp;D is evident from its substantial investment in this area, aligning with industry trends towards enhanced technological capabilities and innovation. The company also actively manages its capital allocation, evidenced by the repurchase of shares worth $55.7 million from October 2025 to February 2026, reflecting confidence in its financial health and future prospects.</p>
<div class="lb-trans"><p>Celestica 最近展现了强劲的财务表现，过去一年盈利增长显著，达到 94.5%，远超电子行业 17.7% 的增长。这一增长得益于其向高需求领域（如人工智能）的战略转型，通过与 AMD 的合作开发先进的网络交换机以支持 AI 平台。此外，Celestica 在研发方面的承诺通过其在该领域的重大投资得以体现，符合行业向增强技术能力和创新的趋势。该公司还积极管理资本配置，反映在 2025 年 10 月至 2026 年 2 月回购价值 5570 万美元的股票上，显示出对其财务健康和未来前景的信心。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Celestica.</li>
<li>Examine Celestica's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Celestica 的动态。</li>
<li>查看 Celestica 的过去表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown"/></p>
<p>TSX:CLS Revenue and Expenses Breakdown as at Mar 2026</p>
<div class="lb-trans"><p>TSX:CLS 截至 2026 年 3 月的收入和支出细分</p>
</div><h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
<div class="lb-trans"><h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Zhen Ding Technology Holding Limited, along with its subsidiaries, is involved in the design, development, manufacture, and sale of printed circuit board products across various international markets including the United States, Mainland China, Taiwan, and Singapore with a market capitalization of NT$222.05 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Zhen Ding Technology Holding Limited 及其子公司涉及印刷电路板产品的设计、开发、制造和销售，市场覆盖美国、中国大陆、台湾和新加坡，市值为 2220.5 亿新台币。</p>
</div><p><strong>Operations:</strong> The company focuses on the design, development, manufacture, and sale of printed circuit boards (PCBs), generating NT$182.52 billion in revenue from this segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司专注于印刷电路板（PCB）的设计、开发、制造和销售，从该部门产生 1825.2 亿新台币的收入。</p>
</div><p>Zhen Ding Technology Holding, despite a recent dip in net income from TWD 9.18 billion to TWD 6.79 billion, continues to show promise with an expected annual earnings growth of 41.2%, outpacing the Taiwan market's average of 21.4%. This robust projection is supported by their aggressive R&amp;D investment strategy, aligning with industry shifts towards advanced tech solutions. The company's participation in multiple high-profile conferences this March underscores its active role in shaping tech discussions regionally, enhancing its industry presence and potentially bolstering future performance.</p>
<div class="lb-trans"><p>尽管 Zhen Ding Technology Holding 最近净收入从 91.8 亿新台币下降至 67.9 亿新台币，但预计年盈利增长为 41.2%，超过台湾市场平均水平 21.4%。这一强劲的预测得益于其积极的研发投资策略，符合行业向先进技术解决方案的转变。该公司在三月份参与多场高端会议，凸显其在区域技术讨论中的积极角色，增强了其行业影响力，并可能提升未来表现。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Zhen Ding Technology Holding's health report.</li>
<li>Learn about Zhen Ding Technology Holding's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在振鼎科技控股健康报告中的详细发现。</li>
<li>了解振鼎科技控股的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:4958 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>TWSE:4958 截至 2026 年 3 月的收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Take a closer look at our Global High Growth Tech and AI Stocks list of 205 companies by clicking here.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里更详细地查看我们全球高增长科技和人工智能股票的 205 家公司名单。</li>
<li>这些公司中有哪一些是你资产组合的一部分吗？利用 Simply Wall St 的投资组合分析功能，全面了解它们的表现。</li>
<li>通过 Simply Wall St 解锁知情投资的力量，这是你在全球股市中导航的免费指南。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容为一般性信息。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票筛选器和警报</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长科技和人工智能公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建你自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

探索 2026 年 3 月的高增长科技股票